Greenspon A J, Volosin K J, Greenberg R M, Jefferies L, Rotmensch H H
Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania.
J Am Coll Cardiol. 1988 Jan;11(1):117-23. doi: 10.1016/0735-1097(88)90176-3.
Forty-two patients with a history of symptomatic ventricular tachycardia or cardiac arrest underwent electrophysiologic testing at control and early in the course of amiodarone therapy (mean 12 +/- 7 days). Late electrophysiologic studies (mean 17 +/- 4 weeks) were repeated in 23 patients on a maintenance dose of 400 mg/day. At control study, all patients had inducible ventricular tachyarrhythmias (sustained ventricular tachycardia in 35, nonsustained ventricular tachycardia in 4, ventricular fibrillation in 3), while after amiodarone loading (1,200 mg daily) 4 (10.5%) of the 42 patients developed noninducible ventricular arrhythmias. At late study, an additional 6 (26%) of the 23 patients with inducible arrhythmias at early study developed noninducible arrhythmias. The cycle length of induced ventricular tachycardia increased from 275 +/- 61 ms at control study to 340 +/- 58 ms at early study (p = 0.001). A further increase in ventricular tachycardia cycle length was noted in patients who underwent both early and late study (341 +/- 38 versus 375 +/- 63 ms, p less than 0.05). The percent of induced tachycardias that were clinically tolerated increased as patients were treated longer with amiodarone (control = 22%, early = 34%, late = 53%, p less than 0.001). Of the 23 patients who had both early and late electrophysiologic studies and were followed up for a mean of 21.7 months (range 4 to 47), there were no recurrences among the 6 patients with noninducible arrhythmias, but there were five recurrences among the 17 patients with persistently inducible arrhythmias. None of the four patients with noninducible arrhythmias at early study had a recurrence. On the basis of these findings, it is concluded that: 1) The timing of programmed electrical stimulation will affect the results of the study in patients treated with oral amiodarone.(ABSTRACT TRUNCATED AT 250 WORDS)
42例有症状性室性心动过速或心脏骤停病史的患者在基线期及胺碘酮治疗早期(平均12±7天)接受了电生理检查。23例接受400mg/天维持剂量治疗的患者进行了后期电生理研究(平均17±4周)。在基线期检查时,所有患者均可诱发出室性快速心律失常(35例持续性室性心动过速,4例非持续性室性心动过速,3例心室颤动),而在胺碘酮负荷量治疗(每日1200mg)后,42例患者中有4例(10.5%)诱发出不可诱发的室性心律失常。在后期研究中,早期研究中23例可诱发性心律失常患者中又有6例(26%)发展为不可诱发性心律失常。诱发性室性心动过速的周长从基线期检查时的275±61ms增加到早期研究时的340±58ms(p=0.001)。在接受早期和后期研究的患者中,室性心动过速周长进一步增加(341±38对375±63ms,p<0.05)。随着患者接受胺碘酮治疗时间延长,临床上可耐受的诱发性心动过速百分比增加(基线期=22%,早期=34%,后期=53%,p<0.001)。在23例接受早期和后期电生理研究且平均随访21.7个月(范围4至47个月)的患者中,6例不可诱发性心律失常患者无复发,但17例持续性可诱发性心律失常患者中有5例复发。早期研究中4例不可诱发性心律失常患者均无复发。基于这些发现,得出以下结论:1)程控电刺激的时机将影响口服胺碘酮治疗患者的研究结果。(摘要截取自250字)